IN THE SPECIFICATION

Page 6, line 18 before Detailed description of the invention insert

- -Brief Description of the Figure

Fig. 1 - shows the in vitro activity of 7-methoxy-8-[3'-(4"-acridonyl carboxamido) propyl]-oxy-(llas) 1, 23, 11a-+etrahydro-5H-pyrrolo[2,1-C][1,4]benzodiazepin-5-one of formula IV against sixty human tumor cells- -

Replace paragraph on page 19, line 20 with the following

- -Cytotoxicity: 7-methoxy-8-[3'-(4"-acridonylcarboxamido)propyl]-oxy--(11aS)1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one.of formula IV was evaluated for primary anti-cancer activity (Table 1) and in vitro against sixty human tumour cells derived from nine cancer types (leukemia, non-small-cell lung, colon, CNS, melanoma, ovarian, prostate, and breast cancer). For each compound, dose response curves for each cell line were measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug exposure was used and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration causing 50% cell growth inhibition (GI50), total cell growth inhibition (TGI 0% growth) and 50% cell death (LC50, -50% growth) compared with the control was calculated. The mean graph midpoint values of log.sub.10TGI and log.sub.10LC50 as well as log.sub.10 GI50 for IV are listed in Table 2. The mean graph itself is shown in ~~Table 4~~ Fig. 1. As demonstrated by mean graph pattern, compound IV exhibits an interesting profile of activity and selectivity for various cell lines. The mean graph mid point of log.sub.10 TGI and log.sub.10 LC50 showed similar pattern to the log.sub.10 GI50 mean graph mid points.- -

Delete page 21.